Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Nocion Therapeutics Announces $62 Million Series B

2024-03-04
WATERTOWN, MA, Nocion Therapeutics, a clinical-stage biopharmaceutical company, announced that it has raised $62 million in Series B funding.
Nocion Therapeutics, a clinical-stage biopharmaceutical company, announced that it has raised $62 million in Series B funding. Nocion is developing first and potentially best in class, small molecule, permanently charged sodium channel blockers (CSCBs), called nocions, that selectively silence activated nociceptors for the treatment of serious conditions involving cough, itch, and pain. Proceeds from the financing will be used to evaluate the lead program, Taplucanium Dry Powder for Inhalation, in a Phase 2b study in Chronic Cough patients.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors